Antimicrobial treatment of asymptomatic carriers of verocytotoxin-producing Escherichia coli: An empiric study

Scandinavian Journal of Infectious Diseases

Volumn 37, Issue 1, 2005, Pages 61-63

  Jensen, Charlotte ^a   Schiellerup, Peter ^a   Olsen, Katharina E P ^a   Scheutz, Flemming ^a   Petersen, Eskild ^a   Gerner Smidt, Peter ^a   Mølbak, Kåre ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CIPROFLOXACIN; NALIDIXIC ACID; VEROTOXIN 1; VEROTOXIN 2;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM CARRIER; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DOT HYBRIDIZATION; ENTEROBACTER INFECTION; ERADICATION THERAPY; ESCHERICHIA COLI; EXPERIENCE; FECES CULTURE; FEMALE; FOLLOW UP; HEMOLYTIC UREMIC SYNDROME; HUMAN; INFECTION CONTROL; MALE; REVIEW; SIDE EFFECT; SOCIAL PROBLEM; SYMPTOM; TREATMENT OUTCOME;

ADULT; AMPICILLIN; ANTI-INFECTIVE AGENTS; CARRIER STATE; CHILD, PRESCHOOL; CIPROFLOXACIN; DENMARK; ESCHERICHIA COLI INFECTIONS; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; INCIDENCE; MALE; MIDDLE AGED; SEROTYPING; SHIGA TOXINS;

EID: 13644260976     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540510026427     Document Type: Review

References (13)

1. Nataro JP, Kaper JB. Diarrhoeagenic Escherichia coli. Clin Microbiol Rev 1998;11:142-201.
2. Chin J. Control of Communicable Diseases Manual. American Public Health Association. 17th edn. 2000.
3. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the haemolytic-uraemic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000;342:1930-6.
4. Kimmitt PT, Harwood CR, Barer MR. Toxin gene expression by shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response. Emerg Infect Dis 2000;6:458-65.
5. Anonymous, 2004. Annual Report on Zoonoses in Denmark 2003, Ministry of Food, Agriculture and Fisheries.
6. Proulx F, Turgeon JP, Delage G, Lafleur L, Chicoine L. Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis. J Pediatr 1992;121: 303.
7. Ohara T, Kojio S, Taneike I, Nakagawa S, Gondaira F, Tamura Y, et al. Effects of azithromycin on shiga toxin production by Escherichia coli and subsequent host inflammatory response. Antimicrob Agents Chemother 2002;46:3478-83.
8. Friedrich AW, Bielaszewska M, Zhang WL, Pulz M, Kuczius T, Ammon A, et al. Escherichia coli harbouring shiga toxin 2 gene variants: frequency and association with clinical symptoms. J Infect Dis 2002;185:74-84.
9. Eklund M, Leino KF, Siitonen A. Clinical Escherichia coli strains carrying stx genes: stx variants and stx-positive virulence profiles. J Clin Microbiol 2002;40:4585-93.
10. Bonnet R, Souweine B, Gauthier G, Rich C, Livrelli V, Sirot J, et al. Non-O157:H7 stx2-producing Escherichia coli strains associated with sporadic cases of hemolyticuremic syndrome in adults. J Clin Microbiol 1998;36:1777-80.
11. Ethelberg S, Olsen KEP, Scheutz F, Jensen C, Schiellerup P, Engberg J, et al. Virulence factors for haemolytic uraemic syndrome, Denmark. Emerg Infect Dis 2004;10:842-7.
12. Boerlin P, McEwen SA, Boerlin-Petzold F, Wilson JB, Johnson RP, Gyles CL. Associations between virulence factors of shiga toxin-producing Escherichia coli and disease in humans. J Clin Microbiol 1999;37:497-503.
13. Karch H. The role of virulence factors in enterohaemorrhagic Escherichia coli (EHEC)-associated haemolyticuraemic syndrome. Semin Thromb Hemost 2001;27: 207-13.